



GLOBAL HEMP GROUP

A HEALTHIER FUTURE THROUGH SUSTAINABLE BUSINESS STRATEGIES

Global Hemp Group (“GHG”) is a Canadian publicly traded company focused on two business segments:

1) **Industrial Hemp:** This division is focused on, but not limited to, the carbon negative use of hemp-based construction materials and carbon neutral bio-energy sources.

2) **Biopharma:** The Health and Wellness Division is acquiring exclusive licensing of patents and other IP. To date the Company has executed agreements for partnerships with Serres Thériault (2021) Inc. (“STI”), B-Organic R&D Corp. and Apollon Formularies plc.

Most recently, GHG executed an Exclusive Option Agreement to acquire STI, a multi-facetted vertically integrated cannabis operator in News Brunswick.

This Option Agreement provides the Company a clear pathway to further diversify its activities in the industry and importantly, access to licenses from Health Canada. This will be an important step in furthering the Company’s R&D ambitions for its Health and Wellness division, which initial foundation encompasses the Exclusive Licenses relating to key patents and IP acquired from Apollon Formularies plc in 2023 and when finalized, B-Organic’s exclusive license for its Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids. GHG will work with these companies in collaboration with Prof. Víctor M. Castaño, Ph.D., head of GHG’s R&D team, to bring together additional advisors that can assist in monetizing this business segment.

The Company continues to work to expand opportunities in these business segments.

Capital Structure

Feb 2024

Shares Issued & Outstanding	24,291,458
Warrants	5,530,000
Options	775,000

Trading CSE: GHG / OTCPK: GBHPF / FRANKFURT: GHGO

Management, Directors, and Advisors

Curt Huber	Interim Pres/CEO/Director
Yousef Kamhiyah	CFO
Ramsey Douglas	Director
Aurelio Useche, MBA, CPA	Director
Nikolas Perrault, CFA	Special Advisor / Capital Markets
Mathieu Couillard, MBA	Advisor Bus Dev & Cap Markets
Prof. Victor Castano, Ph.D.	Advisor, Head of R&D Division
Paul Perrault, Ph.D.	Advisor, Industrial Hemp

Marketing Vision

With the recent addition of Ramsey Douglas as Director of GHG the Company has begun to build its marketing team for products that will be manufactured through outsourcing under various licences. Through his experience in the cannabinoid industry in the United Kingdom and Europe, Ramsey is creating for GHG a comprehensive, end-to-end solution designed to seamlessly connect prescribers, pharmacies, and patients.

The vision behind the marketing strategy is to market through and with partners who already have routes to market, and by understanding their pain points across a complex industry, making sure that the message is consistent, collaborative and hitting the correct audiences. By working in collaboration, it is expected that the Company can generate better growth, with a stronger message, and together get more engagement and reach with brand exposure.

Discussions are underway with a manufacturer to expand the relationship of the parties with the vision to increase the scope of products being marketed in the UK and Europe utilizing the Company’s new connections through Mr. Douglas.

Leading the way in delivering biologically sourced industrial and medical solutions



Exclusive Option Agreement

On January 15, 2024, GHG announced the execution of an Exclusive Option Agreement to Acquire Serres Thériault (2021) Inc. ("STI"), is a Multi-Faceted, Vertically Integrated Cannabis Operator in New Brunswick ("NB"). The STI facility is currently licensed for Cannabis Micro Processing, a Farmgate Retail Store (opening April 2024), Research & Development. The Agreement covers the acquisition of the 8.6-acre compound its five buildings for production and sales, along with property, 6,000 sq ft of Greenhouse, equipment, inventory, genetics, Intellectual Property, and two retail locations. In operation since Nov 2023, the offsite retail location in St. Quentin, NB is one of only eight exclusive private retail outlets located in the province of NB. STI advises that sales at this retail location have exceeded expectations to date and has already reached profitability. Pinnacle Farms, the onsite location is slated to open in April 2024. The store will be licensed as a Farmgate retail model operation in NB with exclusive distribution of products manufactured by STI.

Recent Announcements

- Feb 21, 2024 - [GHG Welcomes Louis Rene Vallee as Business Development Advisor](#)
- Feb 14, 2024 - [GHG Provides Update on its Industrial Hemp Division](#)
- Jan 31, 2024 - [Closing of Debt Settlement](#)
- Jan 15, 2024 - [GHG Announces Execution of Option Agr to Acquire Serres Thériault \(2021\) Inc.](#)
- Oct 11, 2023 - [GHG Executes LOI with B-Organic R&D Corp. to exclusively license its Patented Bioactive Lipid Agents Technology](#)
- Oct 3, 2023 - [GHG Announces Ramsey Douglas Appointed to the Board of Directors](#)
- Mar 21, 2023 - [Global Hemp Group adds Israel, the European Union and Morocco as Exclusive Global Licenses from Apollon Formularies, PLC](#)



B-Organic's patented technology, research has demonstrated that the following can be achieved with cannabinoids:

- to broaden the application field under different dosage forms: tablets, capsules, patch for pharmaceutical apps
- 100 % Generally Recognized As Safe ("GRAS")
- Excipient FDA Cleared
- Increase the bioavailability of the cannabinoids (and its analogues): *less active ingredient is required* in order to target the same dosage or effect
- Conversion process requires **no chemicals, solvents**, or heat
- Costs are low and product is simple to manufacture

GHG acquired the Exclusive Perpetual License for North America (the USA, Canada and Mexico) to certain Apollon Intellectual Property and proprietary technology, including, but not limited to, four key patents and all associated preclinical and clinical data relating to the patents and proprietary technology (the "IP"). The Exclusive Licensing was expanded for the two Composition patents below to include Israel and the European Union with extension to Morocco.

- [Compositions and Methods for Treatment of Cancers](#)
- [Compositions and Methods for Treatment of Inflammation](#)
- [Methods for Treatment of Human Cancers Using Cannabis Compositions](#)
- [Methods for Treatment of Human Cancers Using Mushroom Compositions](#)
- BIOENSIS Preclinical Data reflecting independent 3D cell culture testing of cannabis and mushroom formulations included in the patent applications



These international patents include claims to the treatments of cancers and inflammatory conditions using natural biologics that have been shown in independent, third-party pre-clinical 3D cell culture testing at BIOENSIS laboratories in the United States to kill cancer cells via direct cytotoxicity and immune stimulated cytotoxicity with high efficacy.